Immix Biopharma - A quarter of progress for both lead assets
⬆ $Immix Biopharma Inc(IMMX)$ - Throughout Q323, Immix shared encouraging updates for the clinical development of lead CAR-T asset NXC-201, including the announcement of orphan...
Continue reading on Smartkarma:- https://www.smartkarma.com/insights/immix-biopharma-a-quarter-of-progress-for-both-lead-assets?utm_source=tiger_community
By Edison Investment Research, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/edison-investment-research?utm_source=tiger_community
On Immix Biopharma Inc (IMMX):- https://www.smartkarma.com/entities/immix-biopharma-inc?utm_source=tiger_community
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
